Considering major BP have reviewed the abstract & typically takeovers follow convincing data post ASH conferences, a transaction of some kind could happen a lot sooner than some of us think.
We know Abbvie, BMS, and others were at the table and in discussions around cardio/breast cancer programs prior to DCB departure, now they’ve just reviewed AML synergies with absent toxicity.
If they could put 2+2 together as well as Mason can and draw correlation to FTO inhibition being the reason this combo was effective, I can’t see how they wouldn’t be writing up the paper work now. Why wait until Dec when there’s more eyes & competition.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-33
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
-0.025(1.64%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.55 | $1.50 | $83.06K | 55.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6931 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 1846 | 2 |
View Market Depth
| Last trade - 13.15pm 20/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |